These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26112909)

  • 21. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistics in clinical trials.
    Green SJ; Pauler DK
    Curr Oncol Rep; 2004 Jan; 6(1):36-41. PubMed ID: 14664759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of methods for adaptive treatment selection.
    Friede T; Stallard N
    Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential designs for phase III clinical trials incorporating treatment selection.
    Stallard N; Todd S
    Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
    Jaki T; Hampson LV
    Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data.
    Kunz CU; Friede T; Parsons N; Todd S; Stallard N
    Pharm Stat; 2014; 13(4):238-46. PubMed ID: 24789367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
    Kelly PJ; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating futility of a binary clinical endpoint using early read-outs.
    Van Lancker K; Vandebosch A; Vansteelandt S; De Ridder F
    Stat Med; 2019 Dec; 38(28):5361-5375. PubMed ID: 31631357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
    Nikolakopoulos S; van der Wal WM; Roes KC
    J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Many-to-one comparisons after safety selection in multi-arm clinical trials.
    Hlavin G; Hampson LV; Koenig F
    PLoS One; 2017; 12(6):e0180131. PubMed ID: 28651023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A note on familywise error rate for a primary and secondary endpoint.
    Proschan MA; Follmann DA
    Biometrics; 2023 Jun; 79(2):1114-1118. PubMed ID: 35355244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An adaptive two-stage design with treatment selection using the conditional error function approach.
    Wang J
    Biom J; 2006 Aug; 48(4):679-89. PubMed ID: 16972720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A group-sequential design for clinical trials with treatment selection.
    Stallard N; Friede T
    Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
    Zhou H; Chen C; Sun L; Yuan Y
    Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential design of phase II-III cancer trials.
    Lai TL; Lavori PW; Shih MC
    Stat Med; 2012 Aug; 31(18):1944-60. PubMed ID: 22422502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.